Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Novo Nordisk stock falls after raised forecast fails to change the debate over its obesity business basliginda one cikan gelisme: Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Fonvera editor notu: Haberin piyasa etkisini izlemek icin ilgili varlik sayfalari ve ekonomik takvim akisi birlikte okunmalidir.